Risk appropriate management recommendations for implementing SLNB and imaging were more likely to be made following incorporation of DecisionDx-Melanoma test results.

A tissue systems pathology test may provide an objective method to facilitate earlier therapeutic intervention of Barrett's esophagus patients.

MyPath Melanoma guides dermatologists in treatment decisions leading to a 72% reduction in re-excisions when the GEP result is benign

This work highlights a critical aspect of the physician-patient relationship—communication. As expected, the findings suggest that the verbiage used to describe actinic keratoses (AKs) can affect the patient’s decision to pursue treatment. Interestingly, regardless of how the question was framed, most patients preferred to treat these lesions.

Detection of the field effect in the clinical setting with validated, cost-effective diagnostic assays may increase the detection of HGD and EAC.

Establishes the performance of the gene expression signature in prospectively submitted cases with triple concordant diagnosis

Definitive diagnoses by dermatopathologists in challenging melanocytic lesions increased by 57% by incorporating the results of 23-GEP

Barrett’s esophagus management decisions are often based on subjective diagnoses, so better information and techniques are needed to aid in BE patient care

Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.

TissueCypher better predicts presence of HGD and EAC in BE than pathologic variables, and can improve on histology to identify patients requiring therapy.

Post-test management plans were changed in 53% of patients who had risk aligned management changes concordant with a Class 1 (low risk) or Class 2 result (high risk).

TissueCypher is cost-saving after 5 years and improves patient outcomes due to improving the effectiveness of surveillance and treatment.